OpenLB
Open Library of Bioscience
Advanced Search
mAbs
2012 Jul-Aug;4 (4): 458-65.

Brentuximab vedotin.

Niels W C J van de Donk, Eugen Dhimolea
Author Information
  1. Niels W C J van de Donk: Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA USA. n.w.c.j.vandedonk@umcutrecht.nl
PMID: 22684302 DOI: 10.4161/mabs.20230

Abstract

Brentuximab vedotin (SGN-35; Adcetris®) is an anti-CD30 antibody conjugated via a protease-cleavable linker to the potent anti-microtubule agent monomethyl auristatin E (MMAE). Following binding to CD30, brentuximab vedotin is rapidly internalized and transported to lysosomes where MMAE is released and binds to tubulin, leading to cell cycle arrest and apoptosis. Several trials have shown durable antitumor activity with a manageable safety profile in patients with relapsed/refractory Hodgkin lymphoma, systemic anaplastic large cell lymphoma, or primary cutaneous CD30-positive lymphoproliferative disorders. Peripheral sensory neuropathy is a significant adverse event associated with brentuximab vedotin administration. Neuropathy symptoms are cumulative and dose-related. Multiple ongoing trials are currently evaluating brentuximab vedotin alone or in combination with other agents in relapsed/refractory patients, as well as patients with newly diagnosed disease.

References

  1. Ann Oncol. 2005 Apr;16(4):625-33 [PMID: 15737986]
  2. Blood. 2011 Oct 13;118(15):4024-35 [PMID: 21841159]
  3. Blood. 2003 Aug 15;102(4):1458-65 [PMID: 12714494]
  4. Allergy. 2001 Jul;56(7):593-603 [PMID: 11421916]
  5. N Engl J Med. 2010 Nov 4;363(19):1812-21 [PMID: 21047225]
  6. Blood. 2011 Nov 10;118(19):5119-25 [PMID: 21937701]
  7. J Immunol. 2000 Dec 1;165(11):6170-3 [PMID: 11086050]
  8. Immunol Rev. 2011 Nov;244(1):134-48 [PMID: 22017436]
  9. N Engl J Med. 2004 Sep 30;351(14):1466-7 [PMID: 15459315]
  10. Blood. 2012 Jan 26;119(4):990-6 [PMID: 22147892]
  11. Proc Natl Acad Sci U S A. 1996 Nov 26;93(24):14053-8 [PMID: 8943059]
  12. J Clin Oncol. 1994 Apr;12(4):793-7 [PMID: 8151321]
  13. J Exp Med. 2011 Aug 1;208(8):1579-84 [PMID: 21788408]
  14. J Leukoc Biol. 1995 May;57(5):726-30 [PMID: 7759952]
  15. Blood. 2008 Mar 15;111(6):2977-83 [PMID: 18096762]
  16. Br J Haematol. 2010 Sep;150(5):565-73 [PMID: 20629661]
  17. Br J Haematol. 2009 Jul;146(2):171-9 [PMID: 19466965]
  18. Blood. 2012 Jan 19;119(3):692-5 [PMID: 22117038]
  19. Blood. 2011 Jun 2;117(22):5827-34 [PMID: 21355097]
  20. Am J Pathol. 2000 May;156(5):1723-31 [PMID: 10793083]
  21. J Immunol. 2002 Sep 1;169(5):2451-9 [PMID: 12193714]
  22. J Clin Oncol. 2007 Jul 1;25(19):2764-9 [PMID: 17515574]
  23. Br J Haematol. 2008 Jul;142(1):69-73 [PMID: 18477046]
  24. Blood. 2008 Jun 15;111(12):5496-504 [PMID: 18385450]
  25. J Exp Med. 2002 Sep 16;196(6):829-39 [PMID: 12235215]
  26. J Immunol. 2008 Nov 1;181(9):6316-27 [PMID: 18941223]
  27. Ann Oncol. 2010 Nov;21(11):2246-2254 [PMID: 20423913]
  28. Br J Haematol. 1990 Jun;75(2):282-4 [PMID: 2164839]
  29. Mol Cancer Ther. 2011 Jul;10(7):1127-36 [PMID: 21712478]
  30. J Clin Oncol. 2009 Sep 10;27(26):4357-64 [PMID: 19652067]
  31. Am J Hematol. 2010 May;85(5):320-4 [PMID: 20229590]
  32. Clin Exp Immunol. 2003 Sep;133(3):318-25 [PMID: 12930356]
  33. Clin Cancer Res. 2010 Feb 1;16(3):888-97 [PMID: 20086002]
  34. Cell. 1996 Feb 23;84(4):551-62 [PMID: 8598042]
  35. Br J Haematol. 2010 Nov;151(4):387-96 [PMID: 20880107]
  36. Leuk Lymphoma. 2012 Mar;53(3):506-7 [PMID: 21867368]
  37. Blood. 2008 Feb 15;111(4):1848-54 [PMID: 18079362]
  38. Br J Haematol. 2011 May;153(4):451-85 [PMID: 21480860]
  39. N Engl J Med. 1998 Nov 19;339(21):1506-14 [PMID: 9819449]
  40. Hematology Am Soc Hematol Educ Program. 2010;2010:93-100 [PMID: 21239777]
  41. Clin Cancer Res. 2009 Oct 1;15(19):6217-24 [PMID: 19789316]
  42. Cell. 1993 Jul 2;73(7):1349-60 [PMID: 8391931]
  43. Immunology. 2006 Jun;118(2):143-52 [PMID: 16771849]
  44. Nat Biotechnol. 2003 Jul;21(7):778-84 [PMID: 12778055]
  45. J Clin Oncol. 2012 Jun 20;30(18):2183-9 [PMID: 22454421]
  46. Blood. 1994 Apr 15;83(8):2045-56 [PMID: 8161776]
  47. Clin Cancer Res. 2012 Jan 1;18(1):248-55 [PMID: 22080439]
  48. Biol Blood Marrow Transplant. 2006 Oct;12(10):1065-72 [PMID: 17084370]
  49. Mol Cell Biol. 1997 Mar;17(3):1535-42 [PMID: 9032281]
  50. Clin Cancer Res. 2009 May 15;15(10):3376-83 [PMID: 19401346]

MeSH Term

Apoptosis
Brentuximab Vedotin
Cell Cycle Checkpoints
Clinical Trials as Topic
Hodgkin Disease
Humans
Immunoconjugates
Ki-1 Antigen
Oligopeptides
Protein Binding
Treatment Outcome

Chemicals

Immunoconjugates
Ki-1 Antigen
Oligopeptides
Brentuximab Vedotin
monomethyl auristatin E
Journal Article Research Support, Non-U.S. Gov't Review
Article has an altmetric score of 10

Word Cloud

Created with Highcharts 10.0.0vedotinbrentuximabpatientsBrentuximabMMAEcelltrialsrelapsed/refractorylymphomaSGN-35Adcetris®anti-CD30antibodyconjugatedviaprotease-cleavablelinkerpotentanti-microtubuleagentmonomethylauristatinEFollowingbindingCD30rapidlyinternalizedtransportedlysosomesreleasedbindstubulinleadingcyclearrestapoptosisSeveralshowndurableantitumoractivitymanageablesafetyprofileHodgkinsystemicanaplasticlargeprimarycutaneousCD30-positivelymphoproliferativedisordersPeripheralsensoryneuropathysignificantadverseeventassociatedadministrationNeuropathysymptomscumulativedose-relatedMultipleongoingcurrentlyevaluatingalonecombinationagentswellnewlydiagnoseddisease

Similar Articles

Cited By